Brown, Lisle/Cummings, Inc. Acadia Pharmaceuticals Inc Transaction History
Brown, Lisle/Cummings, Inc.
- $307 Billion
- Q2 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 250 shares of ACAD stock, worth $4,054. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250Holding current value
$4,054% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACAD
# of Institutions
288Shares Held
161MCall Options Held
723KPut Options Held
257K-
Baker Bros. Advisors LP New York, NY42.9MShares$695 Million9.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.7MShares$222 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$222 Million3.72% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$196 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$94.1 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.63B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...